Decision Impact Trial of the ExoDx Prostate (IntelliScore)

NAUnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

September 1, 2018

Study Completion Date

September 29, 2023

Conditions
Cancer of the Prostate
Interventions
DIAGNOSTIC_TEST

ExoDx Prostate (IntelliScore)

ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.

Trial Locations (1)

21204

Chesapeake Urology Research Associates, Towson

All Listed Sponsors
collaborator

CareFirst BlueCross BlueShield

UNKNOWN

collaborator

Chesapeake Urology Research Associates

OTHER

lead

Exosome Diagnostics, Inc.

INDUSTRY